Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595–602.

Article  CAS  PubMed  Google Scholar 

Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–53.

Article  CAS  PubMed  Google Scholar 

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia G, Habibi J, Aroor AR, Martinez-Lemus LA, DeMarco VG, Ramirez-Perez FI, Sun Z, Hayden MR, Meininger GA, Mueller KB, Jaffe IZ, Sowers JR. Endothelial mineralcorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension. 2015;66:1159–67.

Article  CAS  PubMed  Google Scholar 

Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res. 2017;113:411–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolwicz SC Jr, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circul Res. 2013;113:603–16.

Article  CAS  Google Scholar 

Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol. 2010;56:130–40.

Article  CAS  PubMed  Google Scholar 

Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem. 2008;311:215–24.

Article  CAS  PubMed  Google Scholar 

Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267:H742-750.

CAS  PubMed  Google Scholar 

Nakamura M, Liu T, Husain S, Zhai P, Warren JS, Hsu CP, Matsuda T, Phiel CJ, Cox JE, Tian B, Li H, Sadoshima J. Glycogen synthase kinase-3α promotes fatty acid uptake and lipotoxic cardiomyopathy. Cell Metab. 2019;29:1119–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ. Hemodynamic effects of fenofibrate and coenzyme Q10 in Type 2 diabetic subjects with left ventricular diastorlic dysfunction. Diabetes Care. 2008;31:1502–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCommis KS, Douglas DL, Krenz M, Baines CP. Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. J Am Heart Assoc. 2013;2: e000355.

Article  PubMed  PubMed Central  Google Scholar 

Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation. 2009;119:2818–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka N, Mukaiyama K, Morikawa A, Kawakami S, Ichise Y, Kimura T, Horiuchi A. Pemafibrate, a novel selective PPARalpha modulator, attenuates tamoxifen-induced fatty liver disease. Clin J Gastroenterol. 2021;14:846–51.

Article  PubMed  Google Scholar 

Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720–33.

Article  CAS  PubMed  Google Scholar 

Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:63.

Article  PubMed  PubMed Central  Google Scholar 

Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovasc Diabetol. 2021;20:12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung M, Wong VW, Hudson M, Leung DY. Impact of improved glycemic control on cardiac function in Type 2 Diabetes mellitus. Circ Cardiovasc Imaging. 2016;9: e003643.

Article  PubMed  Google Scholar 

Kozakova M, Morizzo C, Fraser AG, Palombo C. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in Type 2 Diabetes mellitus. Cardiovasc Diabetol. 2017;16:78.

Article  PubMed  PubMed Central  Google Scholar 

Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15:457–70.

Article  CAS  PubMed  Google Scholar 

Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202–13.

Article  CAS  PubMed  Google Scholar 

Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by Diabetes mellitus. J Clin Invest. 2002;109:121–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22:5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujimoto R, Ohta Y, Masuda K, Taguchi A, Akiyama M, Yamamoto K, Nakabayashi H, Nagao Y, Matsumura T, Hiroshige S, Kajimura Y, Akashi M, Tanizawa Y. Metabolic state switches between morning and evening in association with circadian clock in people without diabetes. J Diabetes Investig. 2022;13:1496–505.

Article  CAS  PubMed  PubMed Central  Google Scholar